FDA Orange Book
Is there a generic for Myoview 30ml?
Myoview 30ml contains technetium tc-99m tetrofosmin kit. Orange Book status for every listed strength, the approved generic makers, and the listed patents and exclusivities.
Source: FDA Orange Book data file dated 2026-10-09. Publisher page
No. The Orange Book lists no active FDA-approved generic (ANDA) for Myoview 30ml (technetium tc-99m tetrofosmin kit). The Orange Book shows its last listed patent expires March 10, 2030.
Run it in Rivvi
Map Myoview 30ml and your other top fills to their generics
Every strength in RxNorm, with brands that have no generic flagged.
Build the mapFree to start. Opens Rivvi, the AI workspace for healthcare teams.
Myoview 30ml products in the Orange Book
| Form and route | Strength | Brand status | Brand TE | Active generics | Generic TE codes |
|---|---|---|---|---|---|
| injectable, injection | N/A | Marketed (Rx) | None | 0 | None |
NDA 020372, held by MEDI-PHYSICS INC DBA GE HEALTHCARE. Active generics are ANDA products in the Orange Book prescription list with the same ingredient, dosage form, route and strength.
Myoview 30ml patents
| Patent | Expires | Covers | Use code | NDA |
|---|---|---|---|---|
| 9549999 | March 10, 2030 | Drug product | None | 020372 |
Myoview 30ml NDC codes
Questions
Is there a generic for Myoview 30ml?
No. The Orange Book lists no active FDA-approved generic (ANDA) for Myoview 30ml (technetium tc-99m tetrofosmin kit). The Orange Book shows its last listed patent expires March 10, 2030.
What is the generic name for Myoview 30ml?
The active ingredient in Myoview 30ml is technetium tc-99m tetrofosmin kit, per the FDA Orange Book.
When does the Myoview 30ml patent expire?
The last patent listed for Myoview 30ml in the Orange Book expires March 10, 2030. A listed patent expiry date is not a generic launch date.
What does a therapeutic equivalence code mean?
In the Orange Book, codes that start with A (such as AB) mean FDA considers the product therapeutically equivalent to the reference drug. Codes that start with B mean FDA does not, at this time, consider the product therapeutically equivalent.